CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $2.4M, lower than 95% of all stocks globally
- PositionGross margin is -31.6%, lower than 95% of its Biotechnology peers (median 67.2%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
656.22BKRW473.66M · vs all stocks (USD)
Revenue (TTM)
3.32BKRW2.40M · vs all stocks (USD)
Beta
0.8740xvs all stocks
52-Week Change
15.45%vs all stocks
Market Capitalization
656.22BKRW473.66M · vs all stocks (USD)
Enterprise Value
622.93BKRW449.63M · vs all stocks (USD)
Price to Book (MRQ)
6.33xvs Biotechnology peers
Enterprise to Revenue
187.59xvs Biotechnology peers
Enterprise to EBITDA
-34.85xvs Biotechnology peers
Gross Margin
-31.56%vs Biotechnology peers
Operating Margin
-1064.26%vs Biotechnology peers
Return on Assets (TTM)
-9.60%vs Biotechnology peers
Return on Equity (TTM)
-24.29%vs Biotechnology peers
Revenue (TTM)
3.32BKRW2.40M · vs all stocks (USD)
Revenue per Share (TTM)
34.55KRWUpdated Sep 19, 2026Quarterly Revenue Growth
56.30%vs Biotechnology peers
Gross Profit (TTM)
-250.63MKRW-180.91K · vs all stocks (USD)
EBITDA (TTM)
-17.87BKRW-12.90M · vs all stocks (USD)
Net Income (TTM)
-26.44BKRW-19.09M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
56.32%vs Biotechnology peers
Operating Cash Flow (TTM)
-16.50BKRW-11.91M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-9.16BKRW-6.62M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.52BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
3.27BKRWFY2025 · Dec 31, 2025Gross Profit
243.63MKRWFY2025 · Dec 31, 2025Operating Income
-18.16BKRW-13.11M · vs all stocks (USD)
Pre-tax Income
-22.10BKRWFY2025 · Dec 31, 2025Income Tax Expense
3.89MKRWFY2025 · Dec 31, 2025Net Income
-22.13BKRWFY2025 · Dec 31, 2025EBIT
-19.67BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-19.74BKRWFY2025 · Dec 31, 2025Research & Development
7.60BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
5.44BKRWFY2025 · Dec 31, 2025Other Operating Expenses
367.31MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
1.33BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
2.43BKRWFY2025 · Dec 31, 2025EPS (Basic)
-0.2100KRWFY2025 · Dec 31, 2025EPS (Diluted)
-0.2100KRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-22.13BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-24.16BKRWFY2025 · Dec 31, 2025Free Cash Flow
-25.35BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
22.34BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-22.13BKRWFY2025 · Dec 31, 2025Stock-based Compensation
22.60MKRWFY2025 · Dec 31, 2025Other Non-cash Items
477.06MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.09BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-438.52MKRWFY2025 · Dec 31, 2025Capital Expenditures
-1.19BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-19.00BKRWFY2025 · Dec 31, 2025Net Acquisitions
-1.81BKRWFY2025 · Dec 31, 2025Purchase of Investments
-30.18BKRWFY2025 · Dec 31, 2025Sale of Investments
12.15BKRWFY2025 · Dec 31, 2025Other Investing Activity
1.23BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-19.80BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
14.85BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-23.97BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-5.00BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
70.13BKRWFY2025 · Dec 31, 2025Shares Outstanding
96.50MSharesUpdated Sep 19, 2026Float Shares
85.20MSharesUpdated Sep 19, 2026% Held by Insiders
10.19%vs all stocks
% Held by Institutions
8.75%vs all stocks
Total Cash (MRQ)
41.84BKRW30.20M · vs all stocks (USD)
Total Cash per Share (MRQ)
433.51KRWUpdated Sep 19, 2026Total Debt (MRQ)
22.05BKRW15.92M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2135xvs Biotechnology peers
Current Ratio (MRQ)
2.36xvs Biotechnology peers
Book Value per Share (MRQ)
1.07KKRWUpdated Sep 19, 2026Total Assets
130.74BKRW94.37M · vs all stocks (USD)
Total Current Assets
43.99BKRWFY2025 · Dec 31, 2025Total Liabilities
20.01BKRWFY2025 · Dec 31, 2025Total Non-current Assets
86.75BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
491.57MKRWFY2025 · Dec 31, 2025Total Current Liabilities
19.52BKRWFY2025 · Dec 31, 2025Cash Equivalents
22.34BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
22.34BKRWFY2025 · Dec 31, 2025Other Short-term Investments
17.74BKRWFY2025 · Dec 31, 2025Accounts Receivable
2.32BKRWFY2025 · Dec 31, 2025Inventory
1.14BKRWFY2025 · Dec 31, 2025Accounts Payable
498.72MKRWFY2025 · Dec 31, 2025Short-term Debt
17.71BKRWFY2025 · Dec 31, 2025Other Current Liabilities
1.55MKRWFY2025 · Dec 31, 2025Long-term Debt
70.44MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-100.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
48.02BKRWFY2025 · Dec 31, 2025Retained Earnings
-41.69BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
110.73BKRW79.92M · vs all stocks (USD)
Treasury Stock
4.04MKRWFY2025 · Dec 31, 202552-Week Low
4.57KKRWUpdated Sep 19, 202652-Week High
21.50KKRWUpdated Sep 19, 202652-Week Change
15.45%vs all stocks
Beta
0.8740xvs all stocks
50-Day MA
6.66KKRWUpdated Sep 19, 2026200-Day MA
9.57KKRWUpdated Sep 19, 2026Avg 10-Day Volume
2.20MSharesUpdated Sep 19, 2026Avg 30-Day Volume
1.35MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-0.2100KRWUpdated Sep 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -31.6%, lower than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: -0.32Industry median: 0.67Industry P5: 0.14Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $2.4M, lower than 95% of all stocks globallySignificant
Revenue (USD): 2,396,911.31Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Kawin Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jenscare Scientific Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Avacta Group Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Beijing Leadman Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
GoldQuest Mining Corp.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Dongguan Eontec Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Paramita Bangun Sarana Tbk
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown